
12/15/2021 11:42:53 PM - Request Error, reqId: -1, Error Cause: Market data farm connection is OK:usfarm.nj (ERROR)
NoneType: None

12/15/2021 11:42:53 PM - Request Error, reqId: -1, Error Cause: Market data farm connection is OK:cashfarm (ERROR)
NoneType: None

12/15/2021 11:42:53 PM - Request Error, reqId: -1, Error Cause: Market data farm connection is OK:usfarm (ERROR)
NoneType: None

12/15/2021 11:42:53 PM - Request Error, reqId: -1, Error Cause: HMDS data farm connection is OK:fundfarm (ERROR)
NoneType: None

12/15/2021 11:42:53 PM - Request Error, reqId: -1, Error Cause: HMDS data farm connection is OK:ushmds (ERROR)
NoneType: None

12/15/2021 11:42:53 PM - Request Error, reqId: -1, Error Cause: Sec-def data farm connection is OK:secdefil (ERROR)
NoneType: None

12/15/2021 11:42:54 PM - Action: scannerDataEnd, reqId: 0, Ticker list length: 20, Result: ['AVCT', 'CCMP', 'BFRI', 'GMTX', 'MCLD', 'NXTD', 'VIR', 'CNEY', 'MESO', 'MTL PR', 'PRLD', 'MTCR', 'TNDM', 'YANG', 'CONN', 'ENDP', 'BYSI', 'GDXD', 'NRGD', 'LLY'] (DEBUG)

12/15/2021 11:43:05 PM - Action: historicalData, reqId: 1, Rank: 0, Ticker: AVCT, Bar datetime: 2021-12-15, Open: 1.2711, High: 1.65, Low: 1.25, Close: 1.6, Avgerage: 1.47738, Volume: 31390327.00 (DEBUG)

12/15/2021 11:43:05 PM - Action: historicalDataEnd, reqId: 1, Rank: 0, Ticker: AVCT, Bar start time: 2021-12-15, Bar end time: 2021-12-15 (DEBUG)

'<?xml version="1.0" encoding="UTF-8"?>\r\n<ReportSnapshot Major="1" Minor="0" Revision="1">\r\n\t<CoIDs>\r\n\t\t<CoID Type="RepNo">0A443</CoID>\r\n\t\t<CoID Type="CompanyName">Gemini Therapeutics Inc</CoID>\r\n\t\t<CoID Type="IRSNo">851613057</CoID>\r\n\t\t<CoID Type="CIKNo">0001816736</CoID>\r\n\t\t<CoID Type="OrganizationPermID">5076167270</CoID>\r\n\t</CoIDs>\r\n\t<Issues>\r\n\t\t<Issue ID="1" Type="C" Desc="Common Stock" Order="1">\r\n\t\t\t<IssueID Type="Name">Ordinary Shares</IssueID>\r\n\t\t\t<IssueID Type="Ticker">GMTX</IssueID>\r\n\t\t\t<IssueID Type="RIC">GMTX.O</IssueID>\r\n\t\t\t<IssueID Type="DisplayRIC">GMTX.OQ</IssueID>\r\n\t\t\t<IssueID Type="InstrumentPI">449819203</IssueID>\r\n\t\t\t<IssueID Type="QuotePI">449819205</IssueID>\r\n\t\t\t<IssueID Type="InstrumentPermID">25727342637</IssueID>\r\n\t\t\t<IssueID Type="QuotePermID">25727342635</IssueID>\r\n\t\t\t<Exchange Code="NASD" Country="USA">NASDAQ</Exchange>\r\n\t\t\t<GlobalListingType>OSR</GlobalListingType>\r\n\t\t</Issue>\r\n\t\t<Issue ID="2" Type="C" Desc="Common Stock" Order="2">\r\n\t\t\t<IssueID Type="Name">Ordinary Shares Class B</IssueID>\r\n\t\t\t<IssueID Type="InstrumentPI">452554513</IssueID>\r\n\t\t\t<IssueID Type="InstrumentPermID">21763746234</IssueID>\r\n\t\t\t<Exchange Code="NA" Country="">Not Available</Exchange>\r\n\t\t</Issue>\r\n\t</Issues>\r\n\t<CoGeneralInfo>\r\n\t\t<CoStatus Code="1">Active</CoStatus>\r\n\t\t<CoType Code="EQU">Equity Issue</CoType>\r\n\t\t<LastModified>2021-11-22</LastModified>\r\n\t\t<LatestAvailableAnnual>2020-12-31</LatestAvailableAnnual>\r\n\t\t<LatestAvailableInterim>2021-09-30</LatestAvailableInterim>\r\n\t\t<SharesOut Date="2021-11-09" TotalFloat="33406386.0">86225484.0</SharesOut>\r\n\t\t<ReportingCurrency Code="USD">U.S. Dollars</ReportingCurrency>\r\n\t\t<MostRecentExchange Date="2021-12-13">1.0</MostRecentExchange>\r\n\t</CoGeneralInfo>\r\n\t<TextInfo>\r\n\t\t<Text Type="Business Summary" lastModified="2021-02-08T04:09:55">Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company\'s lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH is a construct that express GEM103 continuously at a therapeutic level. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.</Text>\r\n\t\t<Text Type="Financial Summary" lastModified="2021-11-22T01:38:25">BRIEF: For the nine months ended 30 September 2021, GeminiTherapeutics Inc revenues was not reported. Net lossincreased from $501K to $54M. Basic Earnings per Shareexcluding Extraordinary Items decreased from -$0.03 to-$1.41.</Text>\r\n\t</TextInfo>\r\n\t<contactInfo lastUpdated="2021-11-22T01:38:26">\r\n\t\t<streetAddress line="1">300 One Kendall Square</streetAddress>\r\n\t\t<streetAddress line="2">3Rd Floor, Suite 4500</streetAddress>\r\n\t\t<streetAddress line="3"></streetAddress>\r\n\t\t<city>CAMBRIDGE</city>\r\n\t\t<state-region>MA</state-region>\r\n\t\t<postalCode>02139</postalCode>\r\n\t\t<country code="USA">United States</country>\r\n\t\t<contactName></contactName>\r\n\t\t<contactTitle></contactTitle>\r\n\t\t<phone>\r\n\t\t\t<phone type="mainphone">\r\n\t\t\t\t<countryPhoneCode>1</countryPhoneCode>\r\n\t\t\t\t<city-areacode>617</city-areacode>\r\n\t\t\t\t<number>4014400</number>\r\n\t\t\t</phone>\r\n\t\t\t<phone type="mainfax">\r\n\t\t\t\t<countryPhoneCode>1</countryPhoneCode>\r\n\t\t\t\t<city-areacode>302</city-areacode>\r\n\t\t\t\t<number>6365454</number>\r\n\t\t\t</phone>\r\n\t\t</phone>\r\n\t</contactInfo>\r\n\t<webLinks lastUpdated="2021-02-08T11:00:02"><webSite mainCategory="Home Page">https://geminitherapeutics.com/</webSite><eMail mainCategory="Company Contact/E-mail">gemini@argotpartners.com</eMail></webLinks>\r\n\t<peerInfo lastUpdated="2021-11-22T01:38:26">\r\n\t\t<IndustryInfo>\r\n\t\t\t<Industry type="TRBC" order="1" reported="0" code="5620201010" mnem="">Biotechnology &amp; Medical Research (NEC)</Industry>\r\n\t\t\t<Industry type="NAICS" order="1" reported="0" code="541711" mnem="">Research and Development in Biotechnology</Industry>\r\n\t\t\t<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>\r\n\t\t</IndustryInfo>\r\n\t</peerInfo>\r\n\t<officers>\r\n\t\t<officer rank="1" since="05/2021">\r\n\t\t\t<firstName>Georges</firstName>\r\n\t\t\t<mI></mI>\r\n\t\t\t<lastName>Gemayel</lastName>\r\n\t\t\t<age>61 </age>\r\n\t\t\t<title startYear="2021" startMonth="10" startDay="04" iD1="CHM" abbr1="Chmn." iD2="DRC" abbr2="Dir.">Chairman of the Board</title>\r\n\t\t</officer>\r\n\t\t<officer rank="2" since="NA">\r\n\t\t\t<firstName>Jason</firstName>\r\n\t\t\t<mI></mI>\r\n\t\t\t<lastName>Meyenburg</lastName>\r\n\t\t\t<age>44 </age>\r\n\t\t\t<title startYear="2019" startMonth="09" startDay="" iD1="PRE" abbr1="Pres." iD2="CEO" abbr2="CEO">President, Chief Executive Officer, Director</title>\r\n\t\t</officer>\r\n\t\t<officer rank="3" since="02/2021">\r\n\t\t\t<firstName>Brian</firstName>\r\n\t\t\t<mI></mI>\r\n\t\t\t<lastName>Piekos</lastName>\r\n\t\t\t<age>47 </age>\r\n\t\t\t<title startYear="2021" startMonth="10" startDay="04" iD1="CFO" abbr1="CFO" iD2="" abbr2="">Chief Financial Officer, Chief Business Officer</title>\r\n\t\t</officer>\r\n\t\t<officer rank="4" since="03/2020">\r\n\t\t\t<firstName>Marc</firstName>\r\n\t\t\t<mI></mI>\r\n\t\t\t<lastName>Uknis</lastName>\r\n\t\t\t<age>56 </age>\r\n\t\t\t<title startYear="2020" startMonth="03" startDay="" iD1="OTH" abbr1="Other" iD2="" abbr2="">Chief Medical Officer</title>\r\n\t\t</officer>\r\n\t</officers>\r\n\t<Ratios PriceCurrency="USD" ReportingCurrency="USD" ExchangeRate="1.00000" LatestAvailableDate="2021-09-30">\r\n\t\t<Group ID="Price and Volume">\r\n\t\t\t<Ratio FieldName="NPRICE" Type="N">2.43000</Ratio>\r\n\t\t\t<Ratio FieldName="NHIG" Type="N">19.08500</Ratio>\r\n\t\t\t<Ratio FieldName="NLOW" Type="N">2.28000</Ratio>\r\n\t\t\t<Ratio FieldName="PDATE" Type="D">2021-12-14T00:00:00</Ratio>\r\n\t\t\t<Ratio FieldName="VOL10DAVG" Type="N">0.11333</Ratio>\r\n\t\t\t<Ratio FieldName="EV" Type="N">-38.65800</Ratio>\r\n\t\t</Group>\r\n\t\t<Group ID="Income Statement">\r\n\t\t\t<Ratio FieldName="MKTCAP" Type="N">104.76400</Ratio>\r\n\t\t\t<Ratio FieldName="TTMREV" Type="N">0.00000</Ratio>\r\n\t\t\t<Ratio FieldName="TTMEBITD" Type="N">-51.38658</Ratio>\r\n\t\t\t<Ratio FieldName="TTMNIAC" Type="N">-54.35758</Ratio>\r\n\t\t</Group>\r\n\t\t<Group ID="Per share data">\r\n\t\t\t<Ratio FieldName="TTMEPSXCLX" Type="N">-1.42853</Ratio>\r\n\t\t\t<Ratio FieldName="TTMREVPS" Type="N">0.00000</Ratio>\r\n\t\t\t<Ratio FieldName="QBVPS" Type="N">3.26727</Ratio>\r\n\t\t\t<Ratio FieldName="QCSHPS" Type="N">3.48085</Ratio>\r\n\t\t\t<Ratio FieldName="TTMCFSHR" Type="N">-1.62130</Ratio>\r\n\t\t\t<Ratio FieldName="TTMDIVSHR" Type="N">0.00000</Ratio>\r\n\t\t</Group>\r\n\t\t<Group ID="Other Ratios">\r\n\t\t\t<Ratio FieldName="TTMGROSMGN" Type="N">-99999.99000</Ratio>\r\n\t\t\t<Ratio FieldName="TTMROEPCT" Type="N">-42.06570</Ratio>\r\n\t\t\t<Ratio FieldName="TTMPR2REV" Type="N">-99999.99000</Ratio>\r\n\t\t\t<Ratio FieldName="PEEXCLXOR" Type="N">-99999.99000</Ratio>\r\n\t\t\t<Ratio FieldName="PRICE2BK" Type="N">0.74374</Ratio>\r\n\t\t\t<Ratio FieldName="Employees" Type="N">-99999.99000</Ratio>\r\n\t\t</Group>\r\n\t</Ratios>\r\n\t<ForecastData ConsensusType="Mean" CurFiscalYear="2021" CurFiscalYearEndMonth="12" CurInterimEndCalYear="2021" CurInterimEndMonth="12" EarningsBasis="PRX">\r\n\t\t<Ratio FieldName="ConsRecom" Type="N">\r\n\t\t\t<Value PeriodType="CURR">1</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="TargetPrice" Type="N">\r\n\t\t\t<Value PeriodType="CURR">19.66670</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjLTGrowthRate" Type="N">\r\n\t\t\t<Value PeriodType="CURR">-99999.99000</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjPE" Type="N">\r\n\t\t\t<Value PeriodType="CURR">-1.31707</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjSales" Type="N">\r\n\t\t\t<Value PeriodType="CURR">0.00000</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjSalesQ" Type="N">\r\n\t\t\t<Value PeriodType="CURR">0.00000</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjEPS" Type="N">\r\n\t\t\t<Value PeriodType="CURR">-1.84500</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjEPSQ" Type="N">\r\n\t\t\t<Value PeriodType="CURR">-0.46000</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjProfit" Type="N">\r\n\t\t\t<Value PeriodType="CURR">-73.85000</Value>\r\n\t\t</Ratio>\r\n\t\t<Ratio FieldName="ProjDPS" Type="N">\r\n\t\t\t<Value PeriodType="CURR">-99999.99000</Value>\r\n\t\t</Ratio>\r\n\t</ForecastData>\r\n</ReportSnapshot>\r\n'
